Tyra oral dabogratinib posts 79% ORR and 64% CR in Phase 2
Tyra Biosciences said oral dabogratinib in Phase 2 LG IR NMIBC showed favorable safety and strong efficacy: 79% ORR and 64% CR at 60 mg QD, supporting Phase 3 advancement and higher-dose exploration.